Bliss GVS Pharma Share Price

Bliss GVS Pharma

CMP as on 28-Oct-21 10:52

₹ 104.85
-1.40 -1.32%

Open

₹ 106.40

Turnover (lac)

₹ 214

Prev. Close

₹ 106.25

Day's Vol (shares)

₹ 2,04,330

Day's Range (₹)

₹ 104.50
₹ 107.60

CMP as on28-Oct-21 10:40

₹ 104.80
-1.3 -1.23%

Open

₹ 106.85

Turnover (lac)

₹ 394

Prev. Close

₹ 106.10

Day's Vol (shares)

₹ 12,991

Day's Range

₹ 104.55
₹ 107.65

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 23-Jul-2021 - -
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Saturday, July 31, 2021 at the registered office of the Company to consider and approve, inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Companys Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01, 2021 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30, 2021. We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, July 31, 2021 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the matters as per attachment. (As per BSE Announcement Dated on 31/07/2021)
Board Meeting - 03-May-2021 - -
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board Meeting of the Company will be held on Tuesday, May 11, 2021 at the registered office of the Company, inter alia, to transact the following: a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2021 along with the Statement of Assets and Liabilities, Cash Flow Statement and take note of Audit Report with modified opinion, if any, thereon.; b) To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31, 2021; and c) To discuss and recommend the Final Dividend, if any, for the financial year ended March 31, 2021. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2021, subject to approval of the shareholders in the forthcoming Annual General Meeting of the Company. 1. Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2021 along with the audit report with declaration of unmodified opinion 2. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2021 3.Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor 4. Issue & Allotment of 2,10,500 Equity Shares of face value of Rs. 1 each of the Company under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 5.Re-appointment of Mr. Santosh Laxman Parab (DIN:01622988), as an Non-Executive Independent Director of the Company 6. Resignation of Mr. S N Kamath from the position of Managing Director 7. Appointment of Mr. Gagan Harsh Sharma (DIN:07939421) as Managing Director of the Company 8. Reconstitution of Committees 1. Resignation of Mr. S N Kamath from the position of Managing Director as well as membership from all committees of board of the Company with immediate effect i.e. May 11, 2021; 2. Re-appointment of Mr. Santosh Laxman Parab (DIN:01622988), as an Non-Executive Independent Director of the Company for a further period of 5 years with effect from 26th May, 2021 to 25th May, 2026; 3. Appointment of Mr. Gagan Harsh Sharma (DIN:07939421) as Managing Director of the Company for a period of Three years with effect from 11th May, 2021 to 10th May, 2024. With reference to our earlier intimation of Outcome of Board Meeting made to your good office (BSE & NSE) on 11th May, 2021, regarding Appointment of Mr. Gagan Harsh Sharma as Managing Director and Re-appointment of Mr. Santosh Parab as Non-Executive Independent Director of the Company. This is to inform you that, while considering the appointment of Mr. Gagan Harsh Sharma as Managing Director and Re-appointment of Mr. Santosh Parab as Non-Executive Independent Director, the Nomination and Remuneration Committee & Board of Directors of the Company has verified and confirmed from them that they are not debarred from holding the office of Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that, Mr. Gagan Harsh Sharma being appointed as Managing Director and Mr. Santosh Parab appointed as Non-Executive Independent Director are not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. (As Per BSE Announcement Dated on 11.05.2021)
Board Meeting - 13-Jan-2021 - -
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Thursday, January 21, 2021 at the registered office of the Company to consider and approve, inter alia, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2020. We would like to inform you that, Board Meeting of the Company was held today i.e. on Thursday, January 21, 2021 at the registered office of the Company. In pursuant to regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters amongst others: 1. The Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2020. 2. Appointment of Mr. Gagan Harsh Sharma (DIN: 07939421) as an Additional Director (Executive Director) of the Company w.e.f. January 21, 2021. (As per BSE Announcement Dated on 21/01/2021)
Open ZERO Brokerage Demat Account